Abingdon Health (Abingdon Health) LT-Debt-to-Total-Asset : 0.19 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Abingdon Health LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Abingdon Health's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.19.

Abingdon Health's long-term debt to total assets ratio increased from Dec. 2022 (0.14) to Dec. 2023 (0.19). It may suggest that Abingdon Health is progressively becoming more dependent on debt to grow their business.

Abingdon Health LT-Debt-to-Total-Asset Historical Data

The historical data trend for Abingdon Health's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abingdon Health LT-Debt-to-Total-Asset Chart

Abingdon Health Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.11

0.03

0.08

0.15

Abingdon Health Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial					0.03	0.08	0.14	0.15	0.19

Abingdon Health LT-Debt-to-Total-Asset Calculation

Abingdon Health's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (A: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2023 )	/	Total Assets (A: Jun. 2023 )
	=	1.177	/	7.653
	=	0.15

Abingdon Health's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	1.153	/	6.104
	=	0.19

Abingdon Health (OTCPK:ABDXF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Abingdon Health LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Abingdon Health's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Abingdon Health (Abingdon Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Abingdon Health PLC (OTCPK:ABDXF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ABDX:UK

Address

York Biotech Campus, Sand Hutton, York, GBR, YO41 1LZ

Website

https://www.abingdonhealth.com

Abingdon Health PLC is a technology-enabled lateral flow diagnostics company. It provides rapid testing solutions to clients in healthcare and other industries. The firm's product ABC-19 is an antibody test for Covid-19 , and also produces tests covering areas such as self-test HIV, equine infection, human fertility, etc. Business operating segments includes; Contract Development comprises development work for third parties. Contract Manufacturing comprises contract development and manufacturing activities. Product Sales comprises the sale of ABC-19, Pocket Diagnostic products, PCRD tests and antibodies for research use. Key revenue comes from Contract Development segment. Geographically it operates and earns revenue from the UK, USA and Canada, Europe and the rest of the world.

Abingdon Health (Abingdon Health) Headlines

From GuruFocus

AbC-19� Rapid Test Available for Purchase by Healthcare Professionals

By Business Wire Business Wire • 02-16-2021